Transcat (TRNS) Competitors $90.43 +4.40 (+5.11%) Closing price 04:00 PM EasternExtended Trading$90.38 -0.06 (-0.06%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TRNS vs. TXG, EYPT, ALNT, AEHR, CTKB, LAB, SENS, FEIM, MASS, and QSIShould you be buying Transcat stock or one of its competitors? The main competitors of Transcat include 10x Genomics (TXG), Eyepoint Pharmaceuticals (EYPT), Allient (ALNT), Aehr Test Systems (AEHR), Cytek Biosciences (CTKB), Standard BioTools (LAB), Senseonics (SENS), Frequency Electronics (FEIM), 908 Devices (MASS), and Quantum-Si (QSI). These companies are all part of the "measuring and control equipment" industry. Transcat vs. Its Competitors 10x Genomics Eyepoint Pharmaceuticals Allient Aehr Test Systems Cytek Biosciences Standard BioTools Senseonics Frequency Electronics 908 Devices Quantum-Si 10x Genomics (NASDAQ:TXG) and Transcat (NASDAQ:TRNS) are both small-cap measuring and control equipment companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk. Does the media refer more to TXG or TRNS? In the previous week, 10x Genomics had 9 more articles in the media than Transcat. MarketBeat recorded 11 mentions for 10x Genomics and 2 mentions for Transcat. Transcat's average media sentiment score of 1.06 beat 10x Genomics' score of 0.61 indicating that Transcat is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 10x Genomics 3 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Transcat 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders have more ownership in TXG or TRNS? 84.7% of 10x Genomics shares are held by institutional investors. Comparatively, 98.3% of Transcat shares are held by institutional investors. 9.4% of 10x Genomics shares are held by company insiders. Comparatively, 2.8% of Transcat shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has more risk and volatility, TXG or TRNS? 10x Genomics has a beta of 2.03, indicating that its share price is 103% more volatile than the S&P 500. Comparatively, Transcat has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500. Do analysts rate TXG or TRNS? 10x Genomics presently has a consensus price target of $13.54, indicating a potential downside of 5.30%. Transcat has a consensus price target of $112.20, indicating a potential upside of 24.07%. Given Transcat's stronger consensus rating and higher probable upside, analysts clearly believe Transcat is more favorable than 10x Genomics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 10x Genomics 1 Sell rating(s) 6 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.38Transcat 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60 Is TXG or TRNS more profitable? Transcat has a net margin of 4.64% compared to 10x Genomics' net margin of -13.13%. Transcat's return on equity of 6.66% beat 10x Genomics' return on equity.Company Net Margins Return on Equity Return on Assets 10x Genomics-13.13% -12.88% -10.03% Transcat 4.64%6.66%5.09% Which has better valuation and earnings, TXG or TRNS? Transcat has lower revenue, but higher earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Transcat, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio10x Genomics$610.78M2.91-$182.63M-$0.70-20.43Transcat$288.14M2.92$14.52M$1.4363.24 SummaryTranscat beats 10x Genomics on 11 of the 16 factors compared between the two stocks. Get Transcat News Delivered to You Automatically Sign up to receive the latest news and ratings for TRNS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TRNS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRNS vs. The Competition Export to ExcelMetricTranscatINSTRU IndustryComputer SectorNASDAQ ExchangeMarket Cap$842.72M$3.12B$29.55B$9.73BDividend YieldN/A1.00%3.10%4.09%P/E Ratio63.2429.7154.5225.96Price / Sales2.923.101,254.47122.97Price / Cash19.8215.1635.3358.38Price / Book2.883.559.586.39Net Income$14.52M$91.11M$805.43M$265.56M7 Day Performance10.90%3.51%1.58%1.98%1 Month Performance11.38%5.15%-0.11%1.33%1 Year Performance-25.68%17.46%24,107.89%21.15% Transcat Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRNSTranscat2.878 of 5 stars$90.43+5.1%$112.20+24.1%-29.7%$842.72M$288.14M63.241,245Positive NewsAnalyst ForecastTXG10x Genomics3.9007 of 5 stars$13.46+0.7%$13.54+0.6%-43.1%$1.66B$610.78M-19.231,240EYPTEyepoint Pharmaceuticals1.9518 of 5 stars$11.33+2.2%$25.38+124.0%+28.2%$764.41M$43.27M-4.23120Positive NewsALNTAllient2.8755 of 5 stars$44.56+2.4%$35.00-21.5%+110.0%$737.53M$529.97M51.812,525News CoverageAnalyst RevisionAEHRAehr Test Systems1.9425 of 5 stars$19.39+5.9%N/A+22.0%$547.74M$58.97M-149.1490Options VolumeCTKBCytek Biosciences3.597 of 5 stars$4.06+1.2%$5.60+37.9%-25.5%$510.17M$200.45M-81.20500LABStandard BioTools2.5672 of 5 stars$1.27+3.3%$1.55+22.0%-38.1%$467.18M$174.43M-3.97620Positive NewsSENSSenseonics2.4403 of 5 stars$0.47-0.7%$1.55+230.1%+6.2%$382.49M$25.47M-3.6190News CoveragePositive NewsFEIMFrequency Electronics1.3238 of 5 stars$28.38-7.8%N/A+110.5%$299.33M$69.81M11.49200MASS908 Devices2.7489 of 5 stars$6.27-5.4%$8.00+27.6%+42.7%$237.76M$59.63M-11.6160QSIQuantum-Si2.4864 of 5 stars$1.09-0.9%$3.48+218.8%+9.9%$222.74M$3.06M-1.60150 Related Companies and Tools Related Companies TXG Competitors EYPT Competitors ALNT Competitors AEHR Competitors CTKB Competitors LAB Competitors SENS Competitors FEIM Competitors MASS Competitors QSI Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TRNS) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Transcat, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Transcat With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access